<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/21/avadel-pharmaceuticals-plc-nasdaqavdl-director-eric-j-ende-acquires-10000-shares.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-21T12:58:41+00:00"/>
    <meta property="og:title" content="Avadel Pharmaceuticals PLC (NASDAQ:AVDL) Director Eric J. Ende Acquires 10,000 Shares"/>
    <meta property="og:description" content="Avadel Pharmaceuticals PLC (NASDAQ:AVDL) Director Eric J. Ende acquired 10,000 shares of Avadel Pharmaceuticals stock in a transaction on Friday, November 15th. The shares were bought at an average price of $5.32 per share, for a total transaction of $53,200.00. Shares of NASDAQ:AVDL traded down $0.03 during trading on Thursday, hitting $5.47. The company’s stock […]"/>
  </head>
  <body>
    <article>
      <h1>Avadel Pharmaceuticals PLC (NASDAQ:AVDL) Director Eric J. Ende Acquires 10,000 Shares</h1>
      <address><time datetime="2019-11-21T12:58:41+00:00">21 Nov 2019, 12:58</time> by <a rel="author" href="https://www.thecerbatgem.com/author/teresa" target="_blank">Teresa Graham</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/avadel-pharmaceuticals-plc-logo.png"/>
      </figure>
      <p>Avadel Pharmaceuticals PLC (NASDAQ:AVDL) Director Eric J. Ende acquired 10,000 shares of Avadel Pharmaceuticals stock in a transaction on Friday, November 15th. The shares were bought at an average price of $5.32 per share, for a total transaction of $53,200.00.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NASDAQ/AVDL/insider-trades/">NASDAQ:AVDL</a> traded down $0.03 during trading on Thursday, hitting $5.47. The company’s stock had a trading volume of 2,172 shares, compared to its average volume of 310,140. Avadel Pharmaceuticals PLC has a fifty-two week low of $1.03 and a fifty-two week high of $5.75. The stock’s 50-day moving average price is $4.28 and its two-hundred day moving average price is $2.79. The company has a market capitalization of $186.88 million, a PE ratio of -2.77 and a beta of 1.68.</p>
      <p>Avadel Pharmaceuticals (NASDAQ:AVDL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.03. Avadel Pharmaceuticals had a negative return on equity of 608.01% and a negative net margin of 136.46%. The business had revenue of $14.23 million for the quarter. Equities research analysts forecast that Avadel Pharmaceuticals PLC will post -1.06 EPS for the current year.</p>
      <p>Large investors have recently added to or reduced their stakes in the stock. CIBC Private Wealth Group LLC purchased a new stake in Avadel Pharmaceuticals in the 2nd quarter worth approximately $434,000. Renaissance Technologies LLC grew its holdings in Avadel Pharmaceuticals by 21.9% in the 2nd quarter. Renaissance Technologies LLC now owns 802,606 shares of the company’s stock valued at $2,320,000 after buying an additional 144,270 shares in the last quarter. Brown Capital Management LLC lifted its stake in shares of Avadel Pharmaceuticals by 8.9% in the 2nd quarter. Brown Capital Management LLC now owns 1,524,428 shares of the company’s stock valued at $4,406,000 after purchasing an additional 124,421 shares during the last quarter. Susquehanna International Group LLP lifted its stake in Avadel Pharmaceuticals by 263.6% during the 2nd quarter. Susquehanna International Group LLP now owns 98,389 shares of the company’s stock worth $284,000 after acquiring an additional 71,328 shares in the last quarter. Finally, JPMorgan Chase &amp; Co. lifted its stake in Avadel Pharmaceuticals by 383.0% during the 2nd quarter. JPMorgan Chase &amp; Co. now owns 22,700 shares of the company’s stock worth $64,000 after acquiring an additional 18,000 shares in the last quarter. Institutional investors and hedge funds own 50.91% of the company’s stock.</p>
      <p>A number of research analysts have commented on AVDL shares. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> upgraded Avadel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.50 price objective on the stock in a research note on Friday, November 15th. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=AVDL">ValuEngine</a> cut Avadel Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. Finally, Laidlaw boosted their price target on Avadel Pharmaceuticals from $3.00 to $6.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th.</p>
      <p>
        <b>Avadel Pharmaceuticals Company Profile</b>
      </p>
      <p>Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/what-are-treasury-bonds/">What are the risks of holding treasury bonds?</a></p>
    </article>
  </body>
</html>